149 related articles for article (PubMed ID: 11675332)
1. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease.
Leblond V; Lévy V; Maloisel F; Cazin B; Fermand JP; Harousseau JL; Remenieras L; Porcher R; Gardembas M; Marit G; Deconinck E; Desablens B; Guilhot F; Philippe G; Stamatoullas A; Guibon O;
Blood; 2001 Nov; 98(9):2640-4. PubMed ID: 11675332
[TBL] [Abstract][Full Text] [Related]
2. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.
Johnson S; Smith AG; Löffler H; Osby E; Juliusson G; Emmerich B; Wyld PJ; Hiddemann W
Lancet; 1996 May; 347(9013):1432-8. PubMed ID: 8676625
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.
Tam CS; Wolf MM; Westerman D; Januszewicz EH; Prince HM; Seymour JF
Clin Lymphoma Myeloma; 2005 Sep; 6(2):136-9. PubMed ID: 16231852
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen.
Klasa RJ; Meyer RM; Shustik C; Sawka CA; Smith A; Guévin R; Maksymiuk A; Rubinger M; Samosh M; Laplante S; Grenier JF
J Clin Oncol; 2002 Dec; 20(24):4649-54. PubMed ID: 12488409
[TBL] [Abstract][Full Text] [Related]
5. Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis.
Levy V; Porcher R; Delabarre F; Leporrier M; Cazin B; Chevret S;
J Clin Epidemiol; 2001 Jul; 54(7):747-54. PubMed ID: 11438417
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia.
Peinert S; Tam CS; Prince HM; Scarlett J; Wolf MM; Januszewicz EH; Westerman D; Seymour JF
Leuk Lymphoma; 2010 Dec; 51(12):2188-97. PubMed ID: 20939696
[TBL] [Abstract][Full Text] [Related]
7. Evaluating treatment strategies in advanced Waldenström macroglobulinemia: use of quality-adjusted survival analysis.
Lévy V; Porcher R; Leblond V; Fermand JP; Cazin B; Maloisel F; Harousseau JL; Remenieras L; Guibon O; Chevret S;
Leukemia; 2001 Sep; 15(9):1466-70. PubMed ID: 11516109
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia.
Gavriatopoulou M; Kastritis E; Kyrtsonis MC; Vassilakopoulos TP; Roussou M; Fotiou D; Migkou M; Mpakiri M; Tasidou A; Terpos E; Dimopoulos MA
Leuk Lymphoma; 2017 Jun; 58(6):1506-1508. PubMed ID: 27724158
[No Abstract] [Full Text] [Related]
9. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
Leblond V; Johnson S; Chevret S; Copplestone A; Rule S; Tournilhac O; Seymour JF; Patmore RD; Wright D; Morel P; Dilhuydy MS; Willoughby S; Dartigeas C; Malphettes M; Royer B; Ewings M; Pratt G; Lejeune J; Nguyen-Khac F; Choquet S; Owen RG
J Clin Oncol; 2013 Jan; 31(3):301-7. PubMed ID: 23233721
[TBL] [Abstract][Full Text] [Related]
10. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F
Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease.
Tedeschi A; Benevolo G; Varettoni M; Battista ML; Zinzani PL; Visco C; Meneghini V; Pioltelli P; Sacchi S; Ricci F; Nichelatti M; Zaja F; Lazzarino M; Vitolo U; Morra E
Cancer; 2012 Jan; 118(2):434-43. PubMed ID: 21732338
[TBL] [Abstract][Full Text] [Related]
12. Alkylating agents for Waldenstrom's macroglobulinaemia.
Yang K; Tan J; Wu T
Cochrane Database Syst Rev; 2009 Jan; (1):CD006719. PubMed ID: 19160296
[TBL] [Abstract][Full Text] [Related]
13. Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie.
Leblond V; Ben-Othman T; Deconinck E; Taksin AL; Harousseau JL; Delgado MA; Delmer A; Maloisel F; Mariette X; Morel P; Clauvel JP; Duboisset P; Entezam S; Hermine O; Merlet M; Yakoub-Agha I; Guibon O; Caspard H; Fort N
J Clin Oncol; 1998 Jun; 16(6):2060-4. PubMed ID: 9626204
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia.
Tedeschi A; Ricci F; Goldaniga MC; Benevolo G; Varettoni M; Motta M; Pioltelli P; Gini G; Barate' C; Luraschi A; Vismara E; Frustaci AM; Nichelatti M; Vitolo U; Baldini L; Morra E
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):231-4. PubMed ID: 23490992
[TBL] [Abstract][Full Text] [Related]
15. Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial. The French Cooperative Group on Chronic Lymphocytic Leukemia.
Semin Oncol; 1993 Oct; 20(5 Suppl 7):21-3. PubMed ID: 8235691
[TBL] [Abstract][Full Text] [Related]
16. Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
[TBL] [Abstract][Full Text] [Related]
17. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.
O'Brien SM; Kantarjian HM; Cortes J; Beran M; Koller CA; Giles FJ; Lerner S; Keating M
J Clin Oncol; 2001 Mar; 19(5):1414-20. PubMed ID: 11230486
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.
Eichhorst BF; Busch R; Hopfinger G; Pasold R; Hensel M; Steinbrecher C; Siehl S; Jäger U; Bergmann M; Stilgenbauer S; Schweighofer C; Wendtner CM; Döhner H; Brittinger G; Emmerich B; Hallek M;
Blood; 2006 Feb; 107(3):885-91. PubMed ID: 16219797
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine-based combination therapies for Waldenström's macroglobulinemia.
Tedeschi A; Alamos SM; Ricci F; Greco A; Morra E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):67-70. PubMed ID: 19362977
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
